PRF Technologies interim CEO reports option grants

PRF Technologies Ltd. interim CEO Cohen-Arazi Efraim filed an initial ownership report listing direct holdings of several employee stock option grants over the company’s Ordinary Shares.

Rhea-AI Filing Summary

PRF Technologies Ltd. interim CEO Cohen-Arazi Efraim filed an initial ownership report listing direct holdings of several employee stock option grants over the company’s Ordinary Shares. These options give the right to buy shares at exercise prices ranging from 15.7500 to 5400.0000 per share, with expirations between 2031 and 2035.

Footnotes explain that the options were granted under the 2019 PainReform Option Plan and, to qualify for Israeli tax benefits under Section 102, must be registered in the name of a trustee. They also outline vesting schedules, with some grants already fully vested and others vesting in quarterly installments through 2028, contingent on continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Cohen-Arazi Efraim

Role Interim CEO

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--
holding	Employee Stock Option (Right to Buy)(1)( 2)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 50 contracts (Direct); Employee Stock Option (Right to Buy)(1)( 2) — 3,333 contracts (Direct)

Footnotes (6)

1. F1. Options granted under the 2019 PainReform Option Plan.
2. F2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.
3. F3. The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.
4. F4. The grant date of this grant is June 8, 2023. 144 of the options were vested as of the date of appointment. The remaining 6 options will vest on June 8, 2026, subject to the Reporting Person's continued service to the Issuer as of such date.
5. F5. The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
6. F6. The grant date of this grant is February 20, 2025. 750 of the options were vested as of the date of appointment. The remaining 2,250 options will vest in equal quarterly installments beginning on May 20, 2026 until fully vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

FAQ

What does PRF Technologies (PRFX) interim CEO report on this Form 3?

The interim CEO reports his existing holdings of employee stock options. The filing lists several option grants over Ordinary Shares, specifying exercise prices, expiration dates, and vesting terms, providing a baseline view of his derivative equity position with PRF Technologies Ltd.

What stock option positions does Cohen-Arazi Efraim hold in PRF Technologies (PRFX)?

He holds multiple employee stock option grants over Ordinary Shares. The positions include options with exercise prices from 15.7500 to 5400.0000 per share, covering underlying shares such as 50, 150, 183 and 3,000, all reported as directly owned derivative holdings.

How do the PRF Technologies (PRFX) option grants vest for the interim CEO?

The option grants have staggered vesting schedules tied to service. Some grants, like those dated February 23, 2021, are fully vested, while others vest in quarterly installments through dates such as June 8, 2026 and July 18, 2026, conditioned on continued service to the company.

Why are PRF Technologies (PRFX) options held in a trustee’s name?

The options are registered to a trustee for Israeli tax benefits. To qualify under Section 102 of the Israeli Tax Ordinance, securities issued under the 2019 PainReform Option Plan must be held by a trustee, even though they are reported as part of the interim CEO’s option holdings.

What are the key dates for PRF Technologies (PRFX) option grants reported?

Key grant dates include 2021, 2023, 2024 and 2025 issuances. Footnotes highlight grants on February 23, 2021, June 8, 2023, July 18, 2024 and February 20, 2025, with related vesting and expiration timelines extending out to 2035 for the longest-dated grant.

Does this PRF Technologies (PRFX) Form 3 show any recent insider buying or selling?

No open-market buying or selling is reported in this Form 3. The entries are classified as holdings of employee stock options, with no buy or sell transaction codes, describing existing derivative positions rather than new market trades in PRF Technologies shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cohen-Arazi Efraim

(Last) (First) (Middle)

C/O PRF TECHNOLOGIES LTD.

65 YIGAL ALON ST.

(Street)

TEL AVIV 6744316

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PRF Technologies Ltd. [ PRFX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	(3)	02/23/2031	Ordinary Shares	50	$5,400	D
Employee Stock Option (Right to Buy)(1)( 2)	(4)	06/08/2033	Ordinary Shares	150	$706.8	D
Employee Stock Option (Right to Buy)(1)( 2)	(5)	07/18/2034	Ordinary Shares	183	$30	D
Employee Stock Option (Right to Buy)(1)( 2)	(6)	02/20/2035	Ordinary Shares	3,000	$15.75	D

Explanation of Responses:

1. Options granted under the 2019 PainReform Option Plan.

2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.

3. The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.

4. The grant date of this grant is June 8, 2023. 144 of the options were vested as of the date of appointment. The remaining 6 options will vest on June 8, 2026, subject to the Reporting Person's continued service to the Issuer as of such date.

5. The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

6. The grant date of this grant is February 20, 2025. 750 of the options were vested as of the date of appointment. The remaining 2,250 options will vest in equal quarterly installments beginning on May 20, 2026 until fully vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

	/s/ Efraim Cohen-Arazi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)